Published in Pharma Law Weekly, May 23rd, 2006
"The present study uses cell-based screening assays to assess the anticancer effects of targeting phosphatidylinositol 3-kinase-regulated integrin-linked kinase (ILK) in combination with small-molecule inhibitors of Raf-1 or MAPK/extracellular signal-regulated kinase kinase (MEK)," wrote L.A. Edwards and colleagues, BC Cancer Agency.
They continued, "The objective was to determine if synergistic interactions are achievable...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.